We use privacy-friendly analytics — Plausible (cookieless) and Microsoft Clarity, which uses cookies for anonymized heatmaps and session insights — plus advertising tags (LinkedIn Insight Tag and Google Ads) to measure our advertising and show relevant Sydra ads. We never sell your data. See our Cookie Policy and Privacy Policy.
New Jersey · Federal IDR + state pathway
New Jersey runs its own process alongside the federal one. Which applies depends on the plan.
An underpaid Excision of soft tissue tumor of the hand (CPT 26115) claim in New Jersey does not have one dispute route — it has two, and picking the wrong one costs the claim. State-regulated plans follow New Jersey's arbitration, and self-funded plans may opt in. Self-funded ERISA plans that do not opt in follow the federal IDR process. Confirm routing by plan type before filing.
Removal of a subcutaneous soft tissue tumor of the hand or finger.
New Jersey resolves out-of-network payment disputes through binding, baseball-style arbitration administered by Maximus (Out-of-Network Consumer Protection Act, P.L. 2018 c.32; N.J.S.A. 26:2SS). Each side submits a best-and-final offer and the arbiter picks one, referencing FAIR Health percentiles.
Final-offer arbitration with a roughly 30-day decision; studies found median awards several times the in-network rate, anchored to the 80th percentile of charges.
Self-funded plans can voluntarily opt in — a New Jersey-specific feature — expanding which disputes qualify.
Routing decides the deadline. State-regulated plans follow New Jersey's arbitration, and self-funded plans may opt in. Self-funded ERISA plans that do not opt in follow the federal IDR process. Confirm routing by plan type before filing. Two patients can receive the same Excision of soft tissue tumor of the hand at the same facility and their claims follow different processes with different clocks. Confirm plan type against the CMS applicability chart before filing.
The plan pays Excision of soft tissue tumor of the hand at its own qualifying payment amount — its median in-network rate for the area — and treats that as the answer. Under the No Surprises Act the QPA is the plan's opening anchor, not a cap, and certified IDR entities weigh several other factors against it.
With no negotiated rate for Excision of soft tissue tumor of the hand (CPT 26115), the allowed amount is reduced to an out-of-network schedule that rarely reflects what the hand procedure actually involves in a ASC or office setting.
This is the national picture for the code. For the full breakdown see Excision of soft tissue tumor of the hand (CPT 26115), and for every procedure disputed in this state see New Jersey out-of-network IDR.
State-regulated plans follow New Jersey's arbitration, and self-funded plans may opt in. Self-funded ERISA plans that do not opt in follow the federal IDR process. Confirm routing by plan type before filing. For CPT 26115, the deciding factor is the patient's plan type rather than the procedure — the same code can route either way for two different patients at the same facility.
Final-offer arbitration with a roughly 30-day decision; studies found median awards several times the in-network rate, anchored to the 80th percentile of charges. Missing the window forfeits the claim regardless of its merits, which is the most common way a Excision of soft tissue tumor of the hand dispute is lost in New Jersey.
Providers prevail in roughly 88% of federal IDR determinations they contest, and Excision of soft tissue tumor of the hand is asc or office work that is routinely paid below billed charge out of network. The question is usually whether the claim is eligible and the deadline is still open — which is what we check first, at no cost.
Routing and deadlines change at the state line, even for the same procedure and payer.
More hand surgery codes: Hand surgery out-of-network disputes
Send one denied EOB. We will tell you which process it routes to, whether the window is still open, and what the claim is worth — before you commit to anything.
Medically & clinically reviewed by Dr. John M. Abrahams, MD
Board-certified neurosurgeon and founder of Sydra · Last reviewed September 2026 · About the author
Figures reflect the published federal record across all disputes, not a prediction about any individual claim. This is general information, not legal or financial advice.
No outcome is guaranteed. Results vary by claim, payer, specialty, and documentation. Which process applies depends on plan type; confirm routing against the CMS applicability chart before filing. This is general information, not legal or financial advice.